Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Depreciation and Depletion (2021 - 2025)

Historic Depreciation and Depletion for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $120000.0.

  • Amylyx Pharmaceuticals' Depreciation and Depletion fell 4570.14% to $120000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $577000.0, marking a year-over-year decrease of 4478.47%. This contributed to the annual value of $904000.0 for FY2024, which is 1691.18% down from last year.
  • According to the latest figures from Q3 2025, Amylyx Pharmaceuticals' Depreciation and Depletion is $120000.0, which was down 4570.14% from $141000.0 recorded in Q2 2025.
  • Over the past 5 years, Amylyx Pharmaceuticals' Depreciation and Depletion peaked at $315000.0 during Q1 2024, and registered a low of $10000.0 during Q1 2021.
  • Its 5-year average for Depreciation and Depletion is $155157.9, with a median of $160000.0 in 2024.
  • As far as peak fluctuations go, Amylyx Pharmaceuticals' Depreciation and Depletion surged by 155000.0% in 2022, and later crashed by 5047.62% in 2025.
  • Over the past 5 years, Amylyx Pharmaceuticals' Depreciation and Depletion (Quarter) stood at $22000.0 in 2021, then skyrocketed by 727.27% to $182000.0 in 2022, then skyrocketed by 65.38% to $301000.0 in 2023, then crashed by 46.84% to $160000.0 in 2024, then dropped by 25.0% to $120000.0 in 2025.
  • Its last three reported values are $120000.0 in Q3 2025, $141000.0 for Q2 2025, and $156000.0 during Q1 2025.